WO2017202277A1 - 2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法 - Google Patents
2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法 Download PDFInfo
- Publication number
- WO2017202277A1 WO2017202277A1 PCT/CN2017/085421 CN2017085421W WO2017202277A1 WO 2017202277 A1 WO2017202277 A1 WO 2017202277A1 CN 2017085421 W CN2017085421 W CN 2017085421W WO 2017202277 A1 WO2017202277 A1 WO 2017202277A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- derivative
- substituted
- process according
- group
- alkali metal
- Prior art date
Links
- -1 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde Chemical class 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 150000001543 aryl boronic acids Chemical class 0.000 claims abstract description 6
- 150000003935 benzaldehydes Chemical class 0.000 claims abstract description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- 239000000460 chlorine Chemical group 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 7
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 7
- 229910052763 palladium Inorganic materials 0.000 claims description 7
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 5
- 125000006277 halobenzyl group Chemical group 0.000 claims description 5
- 239000003999 initiator Substances 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000011630 iodine Chemical group 0.000 claims description 3
- 229910052740 iodine Chemical group 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 2
- 101150003085 Pdcl gene Proteins 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 150000002941 palladium compounds Chemical class 0.000 claims description 2
- 235000011056 potassium acetate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims 2
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 claims 1
- 238000006555 catalytic reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 abstract 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 18
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 229960002621 pembrolizumab Drugs 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000002955 immunomodulating agent Substances 0.000 description 6
- 229940121354 immunomodulator Drugs 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- GBCABTRJKBMDGW-UHFFFAOYSA-N 4-[[2-bromo-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]methoxy]-5-chloro-2-hydroxybenzaldehyde Chemical compound Oc1cc(OCc2cccc(c2Br)-c2ccc3OCCOc3c2)c(Cl)cc1C=O GBCABTRJKBMDGW-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 4
- 229910001863 barium hydroxide Inorganic materials 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- KEGQEFDADWTVBG-UHFFFAOYSA-N 2-bromo-1-iodo-3-methylbenzene Chemical compound CC1=CC=CC(I)=C1Br KEGQEFDADWTVBG-UHFFFAOYSA-N 0.000 description 3
- RZILUEQOAIVYLY-UHFFFAOYSA-N 4-[(2-bromo-3-phenylphenyl)methoxy]-5-chloro-2-hydroxybenzaldehyde Chemical compound OC1=C(C=O)C=C(C(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)Br)Cl RZILUEQOAIVYLY-UHFFFAOYSA-N 0.000 description 3
- IPOSHVWRFQTHGK-UHFFFAOYSA-N 5-chloro-2,4-dihydroxybenzaldehyde Chemical compound OC1=CC(O)=C(C=O)C=C1Cl IPOSHVWRFQTHGK-UHFFFAOYSA-N 0.000 description 3
- VXKDAXXMZPTOMR-UHFFFAOYSA-N BrC1=C(C=CC=C1C)C1=CC=CC=C1 Chemical compound BrC1=C(C=CC=C1C)C1=CC=CC=C1 VXKDAXXMZPTOMR-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- PJXZIEDLTHQYBC-UHFFFAOYSA-N 2-bromo-1-(bromomethyl)-3-phenylbenzene Chemical compound BrCC1=CC=CC(C=2C=CC=CC=2)=C1Br PJXZIEDLTHQYBC-UHFFFAOYSA-N 0.000 description 2
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 2
- ZIUYBYQBGYMIJL-UHFFFAOYSA-N BrC1=C(OCC2=C(C#N)C(=CC=C2)C2=CC3=C(OCCO3)C=C2)C=C(C(=C1)C=O)O Chemical compound BrC1=C(OCC2=C(C#N)C(=CC=C2)C2=CC3=C(OCCO3)C=C2)C=C(C(=C1)C=O)O ZIUYBYQBGYMIJL-UHFFFAOYSA-N 0.000 description 2
- KUBOISXZFWLUSD-UHFFFAOYSA-N C(#N)C=1C=C(COC2=C(C=O)C=C(C(=C2)OCC2=C(C(=CC=C2)C2=CC=CC=C2)Br)Cl)C=CC=1 Chemical compound C(#N)C=1C=C(COC2=C(C=O)C=C(C(=C2)OCC2=C(C(=CC=C2)C2=CC=CC=C2)Br)Cl)C=CC=1 KUBOISXZFWLUSD-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AKSYJLXZUSYJDO-UHFFFAOYSA-N N-[2-[[4-[[2-cyano-3-(3,4-dimethoxyphenyl)phenyl]methoxy]-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]ethyl]acetamide Chemical compound C(C)(=O)NCCNCC1=C(C=C(C=C1)OCC1=C(C(=CC=C1)C1=CC(=C(C=C1)OC)OC)C#N)OCC1=CC(=CC=C1)C#N AKSYJLXZUSYJDO-UHFFFAOYSA-N 0.000 description 2
- 206010035603 Pleural mesothelioma Diseases 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- WAKZZMMCDILMEF-UHFFFAOYSA-H barium(2+);diphosphate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O WAKZZMMCDILMEF-UHFFFAOYSA-H 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DAKZISABEDGGSV-UHFFFAOYSA-N n-(2-aminoethyl)acetamide Chemical compound CC(=O)NCCN DAKZISABEDGGSV-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012450 pharmaceutical intermediate Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 0 *c1cccc(COc2cc(O)c(C=O)cc2*)c1* Chemical compound *c1cccc(COc2cc(O)c(C=O)cc2*)c1* 0.000 description 1
- DANMWBNOPFBJSZ-UHFFFAOYSA-N 1-iodo-2,3-dimethylbenzene Chemical compound CC1=CC=CC(I)=C1C DANMWBNOPFBJSZ-UHFFFAOYSA-N 0.000 description 1
- WIIBAHCYWOUFRM-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(OCCO2)C2=C1 WIIBAHCYWOUFRM-UHFFFAOYSA-N 0.000 description 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
- MARXMDRWROUXMD-UHFFFAOYSA-N 2-bromoisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(Br)C(=O)C2=C1 MARXMDRWROUXMD-UHFFFAOYSA-N 0.000 description 1
- LEINJSWHIYDUNA-UHFFFAOYSA-N 2-iodo-6-methylbenzonitrile Chemical compound CC1=CC=CC(I)=C1C#N LEINJSWHIYDUNA-UHFFFAOYSA-N 0.000 description 1
- LNHHXJUAOWTQAY-UHFFFAOYSA-N 3-[[5-[[2-bromo-3-(3,4-dimethoxyphenyl)phenyl]methoxy]-4-chloro-2-[(2-hydroxyethylamino)methyl]phenoxy]methyl]benzonitrile Chemical compound OCCNCC1=C(C=C(C(=C1)Cl)OCC1=C(C(=CC=C1)C1=CC(=C(C=C1)OC)OC)Br)OCC1=CC(=CC=C1)C#N LNHHXJUAOWTQAY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YIIXIVBXVLTMHQ-UHFFFAOYSA-N 5-bromo-2,4-dihydroxybenzaldehyde Chemical compound OC1=CC(O)=C(C=O)C=C1Br YIIXIVBXVLTMHQ-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- VSSNRHRWIFCLNK-UHFFFAOYSA-N BrC1=C(COC2=CC(=C(C=O)C=C2Cl)OCC2=CC(=CC=C2)C#N)C=CC=C1C1=CC2=C(OCCO2)C=C1 Chemical compound BrC1=C(COC2=CC(=C(C=O)C=C2Cl)OCC2=CC(=CC=C2)C#N)C=CC=C1C1=CC2=C(OCCO2)C=C1 VSSNRHRWIFCLNK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- PXBHXXRVMRKHFO-UHFFFAOYSA-N ClC=1C(=CC(=C(C=O)C1)O)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(C=O)C1)O)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C PXBHXXRVMRKHFO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- CDMXFARYIXPDJH-UHFFFAOYSA-N OC1=C(C=O)C=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)Br Chemical compound OC1=C(C=O)C=CC(=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)Br CDMXFARYIXPDJH-UHFFFAOYSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- FHUCUPVQDUPROK-UHFFFAOYSA-N acetic acid;antimony Chemical compound [Sb].CC(O)=O FHUCUPVQDUPROK-UHFFFAOYSA-N 0.000 description 1
- 229910001515 alkali metal fluoride Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ITHZDDVSAWDQPZ-UHFFFAOYSA-L barium acetate Chemical compound [Ba+2].CC([O-])=O.CC([O-])=O ITHZDDVSAWDQPZ-UHFFFAOYSA-L 0.000 description 1
- OYLGJCQECKOTOL-UHFFFAOYSA-L barium fluoride Chemical compound [F-].[F-].[Ba+2] OYLGJCQECKOTOL-UHFFFAOYSA-L 0.000 description 1
- 229910001632 barium fluoride Inorganic materials 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
- C07C17/14—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms in the side-chain of aromatic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
- C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/12—Formation of amino and carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/18—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- the invention relates to a preparation method of a compound of the formula (I), that is, a 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative, and belongs to the technical field of medicine.
- the ability of tumor cells to evade the immune system is achieved by binding of a programmed death ligand (PD-L1) produced on its surface to the PD-1 protein of T cells.
- PD-L1 programmed death ligand
- the tumor microenvironment in the body induces high expression of PD-1 molecules in infiltrating T cells, and tumor cells highly express PD-1 ligands PD-L1 and PD-L2, resulting in continuous activation of the PD-1 pathway in the tumor microenvironment.
- T cell function is inhibited and the tumor cannot be found so that it cannot deliver a treatment to the immune system that requires attacking the tumor and killing the tumor cells.
- the PD-1 antibody is an antibody protein against PD-1 or PD-L1, which prevents the first two proteins from binding, blocks this pathway, and partially restores the function of T cells, enabling these cells to continue to kill tumor cells.
- Immunotherapy based on PD1/PDL1 is a new generation of immunotherapy that is currently attracting attention. It aims to use the body's own immune system to resist tumors and induce apoptosis by blocking PD-1/PD-L1 signaling pathway. Tumor potential. Recently, a series of surprising studies have confirmed that PDl/PD-Ll inhibitory antibodies have strong anti-tumor activity against a variety of tumors, which is particularly eye-catching. September 4, 2014, Merck, USA (Pembrolizumab) became the first FDA-approved PD-1 mAb for the treatment of advanced or unresectable melanoma patients who were ineffective for other medications.
- the monoclonal antibody therapeutic drug has its own defects: it is easily decomposed by proteases, so it is unstable in the body and cannot be taken orally; it is easy to produce immune cross-reaction; the product quality is not easy to control, and the production technology is high; a large amount of preparation and purification is difficult, and production is difficult. High cost; inconvenient to use, can only be injected or drip. Therefore, PDl/PD-Ll interaction small molecule inhibitors are a better choice for tumor immunotherapy.
- the 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative represented by the formula (I) of the present invention is an important intermediate of an immunomodulator acting on PD1/PD-L1
- immunomodulators are mainly used for cancer, infectious diseases and autoimmune diseases;
- the preparation method of the present partial 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative (I) is not sufficiently high in yield and is not suitable for industrial production;
- the technical problem to be solved by the present invention is to provide a process for preparing a 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative (I) as a potential pharmaceutical intermediate.
- R1 fluorine, chlorine, bromine, methyl, cyano
- R3 hydrogen, methyl, ethyl, fluorine, chlorine, bromine;
- X is selected from bromine, chlorine, and iodine.
- the preferred route includes the following steps:
- R1 fluorine, chlorine, bromine, methyl, cyano
- R3 hydrogen, methyl, ethyl, fluorine, chlorine, bromine;
- X is selected from bromine, chlorine, and iodine.
- the solvent used can be dried for use in a conventional manner in the art.
- the preparation method of the present invention is as follows
- the raw material of the step 1) is a molar ratio of the 2-substituted-3-iodotoluene derivative 1 and the arylboronic acid 5 or aryl boronic acid ester: 1:0.8-1.5; preferably 1:1;
- the reaction is carried out in a conventional chemical reaction vessel, such as a flask or a reaction vessel.
- a reaction vessel is dried.
- the solvent used for the reaction may be a protic solvent, an aprotic solvent, a polar solvent and a non-polar solvent, or a mixed solvent for the purpose of dissolving the reactants.
- Preferred aprotic solvents are selected from the group consisting of tetrahydrofuran, diethyl ether, dioxane, dimethyl sulfoxide, toluene, N,N-dimethylformamide;
- preferred protic solvents are selected from the group consisting of ethanol, isopropanol, methanol, tert-butanol Water, formic acid, acetic acid, ethylamine; the most preferred solvent is selected from the group consisting of dioxane/water, preferably in a volume ratio of from 1 to 10:1, most preferably 5:1.
- Preferred palladium catalysts for the reaction are zero-valent palladium and divalent palladium compounds; more preferred are triphenylphosphine palladium, tetrakis(triphenylphosphine)palladium, PdCl 2 (dppf); and most preferred tetrakis(triphenylphosphine)palladium.
- the preferred base for the reaction may be selected from the group consisting of alkali metal carbonates, alkali metal acetates, alkali metal and alkaline earth metal hydroxides, alkali metal fluorides, alkali metal phosphates; more preferably from cesium carbonate, potassium carbonate, sodium carbonate, Sodium acetate, potassium acetate, barium acetate, barium hydroxide, potassium hydroxide, barium hydroxide, barium hydroxide, potassium fluoride, barium fluoride, potassium phosphate, barium phosphate, sodium phosphate; most preferred are barium carbonate, acetic acid Antimony, barium hydroxide, barium phosphate.
- the reaction conditions are preferably protected from an inert gas, most preferably argon gas; the reaction conditions preferably control the reaction temperature, and can be controlled between room temperature and 120 ° C, with a preferred reaction temperature of 100 ° C.
- the temperature of the reaction varies depending on the solvent.
- Step 2) preparing a halobenzyl derivative 3;
- step 2) the 2-substituted-3-aryltoluene derivative 2 is used as a raw material to prepare a benzyl halide derivative 3;
- step 2) 2-substituted-3-aryltoluene derivative 2 is reacted with a brominating agent under free radical initiating conditions to prepare a benzyl halide derivative 3.
- 2-substituted-3-aryltoluene derivative 2 and bromination The molar ratio of the agent is 1:0.8-1.5; most preferably 1:1; the molar ratio of the brominating agent to the free radical initiator is 1:0.01-0.10; most preferably 1:0.05;
- Preferred brominating agents for the reaction may be NCS (N-chlorosuccinimide), NBS (N-bromosuccinimide), TBAB (phenyltrimethylammonium tribromide), elemental bromine; The most preferred brominating agent is NBS.
- Preferred free radical initiating conditions for the reaction are the addition of a free radical initiator, light, or both; more preferably plus A radical initiator is introduced; benzoyl peroxide and m-chloroperoxybenzoic acid are preferred; benzoyl peroxide is most preferred.
- the reaction is carried out in a conventional chemical reaction vessel or in an actinic reactor, such as a flask or a tailored actinic reactor. Preferably, the reaction vessel is dried.
- the solvent used in the reaction is preferably selected from carbon tetrachloride, carbon tetrabromide, acetonitrile; most preferred is carbon tetrachloride.
- the reaction conditions preferably control the reaction temperature, and can be controlled between 50 and 85 ° C, and the preferred reaction temperature is 80 ° C.
- the temperature of the reaction varies depending on the solvent.
- Step 3 Preparation of 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde from benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6 as starting materials Derivative (I). ;
- step 3 the benzyl halide derivative 3 and the 2,4-dihydroxy-5-substituted benzaldehyde 6 are selectively prepared under weakly basic conditions to prepare 2-hydroxy-4-(2,3-disubstituted benzyloxy). -5-Substituted benzaldehyde derivative (I).
- the reaction is carried out in a conventional chemical reaction vessel, such as a flask or a reaction vessel.
- a reaction vessel is dried.
- the molar ratio of the raw material benzyl halide derivative 3 and the 2,4-dihydroxy-5-substituted benzaldehyde in the reaction is 1:0.8-1.5; most preferably 1:1;
- the preferred weak base condition in the reaction is the addition of an alkali metal hydrogencarbonate, an alkali metal acetate; a more preferred weak base condition is the addition of sodium hydrogencarbonate or potassium hydrogencarbonate;
- the solvent used in the reaction may be selected from an aprotic polar solvent for the purpose of dissolving the reactant; the preferred aprotic solvent is selected from the group consisting of acetonitrile, tetrahydrofuran, diethyl ether, dioxane, dimethyl sulfoxide, N,N-dimethylformamide.
- the most preferred solvent is selected from the group consisting of acetonitrile, tetrahydrofuran, and N,N-dimethylformamide;
- the reaction conditions preferably control the reaction temperature, and can be controlled between 20 and 85 ° C, and the preferred reaction temperature is 50-60 ° C.
- the temperature of the reaction varies with the solvent
- the invention provides a preparation method of a compound of the formula (I), that is, a 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative, which belongs to the technical field of medicine;
- the 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative (I) is an important intermediate of an immunomodulator; the preparation method has the advantages of high yield and easy industrialization; Part of the intermediate 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative (I) is a potential new pharmaceutical intermediate;
- a 2-substituted-3-aryltoluene derivative 2 is prepared by using a 2-substituted-3-iodotoluene derivative 1 and an arylboronic acid 5 or an aryl boronic acid ester as a raw material, and the raw material is easily obtained. It does not require special reagents, is simple, easy to operate, mild in conditions, high in yield, and easy to industrialize.
- the 2-substituted-3-aryltoluene derivative 2 is reacted with a brominating agent under a free radical initiating condition to prepare a benzyl halide derivative 3, or a 2-substituted-3-aryltoluene derivative 2 and a bromine
- a brominating agent under a free radical initiating condition to prepare a benzyl halide derivative 3, or a 2-substituted-3-aryltoluene derivative 2 and a bromine
- the benzoic acid derivative 3 is prepared by reacting under light conditions, the reaction condition is mild, the yield is high, the post-treatment is easy, the separation is not carried out, and the next reaction is directly carried out, which is easy to industrialize.
- Step 3 Selective preparation of 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzene from benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6
- the formaldehyde derivative (I) has the advantages of few steps, easy operation, economical and practical, and easy industrialization.
- the synthetic route of the present invention is readily available, does not require column chromatography separation, does not require cryogenic equipment,
- the 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative prepared by the preparation method of the invention is an important intermediate of a class of immunomodulators, Examples 2, 4 6,8 is an illustration of such immunomodulators. It can be seen that the compounds of Examples 2, 4, 6, and 8 can significantly inhibit the interaction between PD-1 and PD-L1, and are a novel class of immunomodulators.
- NBS N-bromophthalimide
- 2,4-Dihydroxy-5-chlorobenzaldehyde (73.94 mg) was weighed and placed in a 50 ml single-mouth bottle, dissolved in 6 ml of anhydrous acetonitrile, and then sodium hydrogencarbonate (98.88 mg) was added. After stirring at room temperature for 40 min, 2-bromo-3-phenylbenzyl bromide (192 mg) was dissolved in 8 ml of DMF, and slowly added to the reaction system using a constant pressure dropping funnel, and heated to reflux until the reaction was completed. After cooling to room temperature, water and ethyl acetate were added for extraction. The organic layer was washed with brine, dried over anhydrous sodium sulfate. The yield was 85%.
- the bromination reaction was carried out in the same manner as in Example 1 except that 2-bromo-3-(3,4-ethanedioxyphenyl)toluene was used instead of 2-bromo-3-methyl-1,1'-biphenyl.
- the obtained product was directly subjected to the next reaction with 2,4-dihydroxy-5-chlorobenzaldehyde without isolation, and was operated in the same manner as in Example 1 to give a white solid.
- Examples 1, 3, 5, and 7 are intermediate 2-hydroxy-4-(2,3-disubstituted benzyloxy)-5-substituted benzaldehyde derivatives (I)
- Examples 2, 4, 6, and 8 are immunomodulatory compounds prepared on the basis of Examples 1, 3, 5, and 7, respectively.
- In vitro activity evaluation The in vitro enzymatic level detection method was performed using Cisbio's HTRF detection kit. Screening principle and method of PD-1/PD-L1 small molecule inhibitor
- PD-1 protein carries HIS tag
- PD-1 ligand PD-L1 carries hFc tag
- Eu-labeled anti-hFc antibody and XL665-labeled anti-HIS antibody are combined with two tag proteins, laser After excitation, energy can be transferred from donor Eu to receptor XL665, causing XL665 to emit light, and after addition of inhibitor (compound or antibody), blocking the binding of PD-1 to PD-L1, making Eu and XL665 far apart The energy cannot be transferred and the XL665 does not emit light.
- Example IC 50 (M) Example IC 50 (M) 2 6.23 ⁇ 10 -8 4 2.68 ⁇ 10 -7 6 3.5 ⁇ 10 -8 8 7.12 ⁇ 10 -9
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrrole Compounds (AREA)
Abstract
提供了式(I)化合物2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法,包括如下步骤:(1)以2-取代-3-碘甲苯衍生物1和芳基硼酸5或芳基硼酸酯为原料,制备2-取代-3-芳基甲苯衍生物2;(2)以2-取代-3-芳基甲苯衍生物2为原料,制备苄卤衍生物3;(3)以苄卤衍生物3和2,4-二羟基-5-取代苯甲醛6为原料,制备2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I)。
Description
本发明涉及式(I)化合物即2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法,属于医药技术领域。
随着对肿瘤免疫研究的深入,人们发现肿瘤微环境可以保护肿瘤细胞不被机体免疫系统识别和杀伤,肿瘤细胞的免疫逃逸在肿瘤发生、发展中扮演了非常重要的角色。2013年Science杂志将肿瘤免疫治疗列为十大突破之首,再次让免疫治疗成为肿瘤治疗领域的“焦点”。机体免疫细胞的激活或抑制是通过正性信号和负性信号来调节,其中程序性死亡分子1(programmed death 1,PD-1)/PD-1配体(PD-1ligand,PD-L1)便是负性免疫调节信号,抑制了肿瘤特异性CD8+T细胞的免疫活性,介导了免疫逃逸。
肿瘤细胞所具有的逃避免疫系统的能力,是通过在其表面产生的程序性死亡配体(PD-L1)结合到T细胞的PD-1蛋白上实现的。机体内的肿瘤微环境会诱导浸润的T细胞高表达PD-1分子,肿瘤细胞会高表达PD-1的配体PD-L1和PD-L2,导致肿瘤微环境中PD-1通路持续激活,T细胞功能被抑制而不能发现肿瘤以至于不能向免疫系统发出需要攻击肿瘤和杀伤肿瘤细胞的治疗。PD-1抗体是针对PD-1或者PD-L1的一种抗体蛋白,使得前两种蛋白不能发生结合,阻断这一通路,部分恢复T细胞的功能,使这些细胞能够继续杀伤肿瘤细胞。
基于PD1/PDL1的免疫疗法是当前备受瞩目的新一代免疫疗法,旨在利用人体自身的免疫系统抵御肿瘤,通过阻断PD-1/PD-L1信号通路诱导凋亡,具有治疗多种类型肿瘤潜力。最近,一系列令人惊喜的研究结果证实PDl/PD-Ll抑制性抗体对多种肿瘤具有强大的抗瘤活性,格外引人注目。2014年9月4日美国默克的(pembrolizumab)成为FDA批准的首例PD-1单抗用于治疗对其它药物治疗无效的晚期或无法切除的黑色素瘤患者。目前,默沙东正在30多种不同类型的癌症中调查Keytruda的潜力,包括各类血液癌症、肺癌、乳腺癌、膀胱癌、胃
癌、头颈部癌症。2014年12月22日,制药巨头百时美施贵宝公司不负重望,率先发力,获得美国食品药品监督管理局(FDA)加速批准,其研发的抗癌免疫疗法药物nivolumab以Opdivo的商品名上市,用于治疗对其它药物没有应答的不可切除的或转移性黑色素瘤患者,是继默沙东Keytruda之后第二个在美国上市的PD-1抑制剂。FDA于2015年3月4日批准了nivolumab用于治疗在经铂为基础化疗期间或化疗后发生疾病进展的转移性鳞性非小细胞肺癌。根据默沙东公布的Keytruda(pembrolizumab)治疗实体瘤的一项Ib期KEYNOTE-028研究数据,Keytruda治疗在25例胸膜间皮瘤(pleuralmesothelioma,PM)患者中取得了28%的总缓解率(ORR),并有48%的患者病情稳定,疾病控制率达到了76%。对当前任何已获批药物均无治疗反应的晚期霍奇金淋巴瘤(HL)患者,接受默沙东Keytruda和百时美Opdvio治疗后,能够达到完全缓解。在2015AACR年会上,约翰霍普金斯基梅尔癌症中心(Kimmel Cancer Center)的肿瘤内科学副教授Leisha A.Emens,MD,PhD做出的报道指出,罗氏的MPDL3280A这一具有抗PD-L1作用的单克隆抗体,在晚期三阴性乳腺癌中表现出了持久的疗效。
虽然肿瘤免疫治疗被认为是靶向治疗后癌症治疗的革命。但是,单抗治疗药物有其本身的缺陷:易被蛋白酶分解,因而在体内不稳定,不能口服;易产生免疫交叉反应;产品质量不易控制,制作技术要求高;大量制备和纯化比较困难,生产成本高;使用不方便,只能注射或点滴。所以,PDl/PD-Ll相互作用小分子抑制剂是肿瘤免疫治疗的更佳选择。
本发明式(I)所示的2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物是作用于PDl/PD-Ll的免疫调节剂的重要中间体,该类免疫调节剂主要用于癌症、感染性疾病和自身免疫性疾病;
目前的部分2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I)的制备方法产率不足够高、不宜于工业化生产;
发明内容
本发明要解决的技术问题是提供2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I)作为潜在药物中间体的制备方法。
为实现本发明的目的,采用如下的技术方案制备2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I):
包括以下步骤:
其中:R1=氟、氯、溴、甲基、氰基;
R3=氢、甲基、乙基、氟、氯、溴;
X选自溴、氯、碘。
优选的路线包括以下步骤:
1)以2-取代-3-碘甲苯衍生物1和芳基硼酸5或芳基硼酸酯为原料,制备2-取代-3-芳基甲苯衍生物2;
2)以2-取代-3-芳基甲苯衍生物2为原料,制备苄卤衍生物3;
3)以苄卤衍生物3和2,4-二羟基-5-取代苯甲醛6为原料,制备2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I);
R1=氟、氯、溴、甲基、氰基;
R3=氢、甲基、乙基、氟、氯、溴;
X选自溴、氯、碘。
所用溶剂可按本领域的常规方法干燥备用。
具体而言,本发明的制备的方法如下
步骤1)制备2-取代-3-芳基甲苯衍生物2
步骤1)的原料为2-取代-3-碘甲苯衍生物1和芳基硼酸5或芳基硼酸酯的摩尔比为1∶0.8-1.5;优选是1∶1;
反应在常规的化学反应容器中进行,例如烧瓶或反应釜。优选对反应的容器进行干燥。
反应所用溶剂可选质子溶剂、非质子溶剂、极性溶剂和非极性溶剂,或混合溶剂,以溶解反应物为目的。优选的非质子溶剂选自四氢呋喃,乙醚,二氧六环,二甲亚砜,甲苯,N,N-二甲基甲酰胺;优选的质子溶剂选自乙醇、异丙醇、甲醇、叔丁醇、水、甲酸、乙酸、乙胺;最优选的溶剂选自二氧六环/水,优选的体积比例为1-10:1,最优选5:1。
反应优选的钯催化剂为零价钯和二价钯化合物;更优选三苯膦合钯、四(三苯膦)钯,PdCl2(dppf);最优选的四(三苯膦)钯。
反应优选的碱可选自碱金属碳酸盐、碱金属醋酸盐、碱金属和碱土金属氢氧化物、碱金属氟化物、碱金属磷酸盐;更优选自碳酸铯、碳酸钾、碳酸钠、醋酸钠、醋酸钾、醋酸铯、氢氧化铯、氢氧化钾、氢氧化锶、氢氧化钡、氟化钾、氟化铯、磷酸钾、磷酸铯、磷酸钠;最优选的是碳酸铯、醋酸铯、氢氧化钡、磷酸铯。
反应条件优选自惰性气体保护,最优选氩气保护;反应条件优选控制反应温度,可控制在室温到120℃之间,优选的反应温度为100℃。反应的温度随溶剂不同而变化。
步骤2)制备卤苄衍生物3;
步骤2)中,以2-取代-3-芳基甲苯衍生物2为原料,制备苄卤衍生物3;
步骤2)中,2-取代-3-芳基甲苯衍生物2与溴化剂在自由基引发条件下反应制备苄卤衍生物3。2-取代-3-芳基甲苯衍生物2与溴化剂的摩尔比为1∶0.8-1.5;最优选是1∶1;溴化剂与自由基引发剂的摩尔比为1∶0.01-0.10;最优选是1∶0.05;
反应优选的溴化剂可为NCS(N-氯代丁二酰亚胺)、NBS(N-溴代丁二酰亚胺)、TBAB(苯基三甲基三溴化铵)、单质溴;最优选的溴化剂为NBS。
反应优选的自由基引发条件是加入自由基引发剂、光照、或兼而有之;更优选加
入自由基引发剂;特优选过氧化苯甲酰、间氯过氧苯甲酸;最优选过氧化苯甲酰。反应在常规的化学反应容器中或光化反应器中进行,例如烧瓶或特制的光化反应器。优选对反应的容器进行干燥。
反应所用溶剂优选自四氯化碳、四溴化碳、乙腈;最优选四氯化碳。
反应条件优选控制反应温度,可控制在50到85℃之间,优选的反应温度为80℃。
反应的温度随溶剂不同而变化。
步骤3)以苄卤衍生物3和2,4-二羟基-5-取代苯甲醛6为原料,制备2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I)。;
步骤3)中,苄卤衍生物3和2,4-二羟基-5-取代苯甲醛6在弱碱性条件下选择性制备2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I)。
反应在常规的化学反应容器中进行,例如烧瓶或反应釜。优选对反应的容器进行干燥。
反应中原料苄卤衍生物3和2,4-二羟基-5-取代苯甲醛6摩尔比为1∶0.8-1.5;最优选是1∶1;
反应中优选的弱碱条件是加入碱金属碳酸氢盐,碱金属醋酸盐;更优选的弱碱条件是加入碳酸氢钠或碳酸氢钾;
反应所用溶剂可选非质子极性溶剂,以溶解反应物为目的;优选的非质子溶剂选自乙腈、四氢呋喃、乙醚、二氧六环、二甲亚砜、N,N-二甲基甲酰胺;最优选的溶剂选自乙腈、四氢呋喃、N,N-二甲基甲酰胺;
反应条件优选控制反应温度,可控制在20到85℃之间,优选的反应温度为50-60℃。反应的温度随溶剂不同而变化
有益技术效果:
本发明提供的涉及式(I)化合物即2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法,属于医药技术领域;
2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I)是免疫调节剂的重要中间体;其制备方法具有产率高、易工业化的优点;部分中间体2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I)为新化合物是潜在的医药中间体;
本发明提供的合成路线中:
步骤1)中,以2-取代-3-碘甲苯衍生物1和芳基硼酸5或芳基硼酸酯为原料,制备2-取代-3-芳基甲苯衍生物2的方法,原料易得,不需特殊试剂,简便,易操作,条件温和,高产率,易于工业化。
步骤2)中,2-取代-3-芳基甲苯衍生物2与溴化剂在自由基引发条件下反应制备苄卤衍生物3,或2-取代-3-芳基甲苯衍生物2与溴化剂在光照条件下反应制备苄卤衍生物3,反应条件温和,产率高,后处理容易,不用分离,直接进行下一步反应,易工业化。
步骤3以苄卤衍生物3和2,4-二羟基-5-取代苯甲醛6为原料,选择性制备2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I),具有步骤少,易操作,经济实用,易于工业化的优点。
总之:本发明的合成路线原料易得,不需要柱层析分离,不需要低温设备,
不需要保护基团的引入与消除,反应路线短,易操作,经济实用,适于工业化的制备方法。
以本发明的制备方法制备得到的2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物是一类免疫调节剂的重要中间体,实施例2、4、6、8是该类免疫调节剂的举例说明。可以看出实施例2、4、6、8化合物可显著抑制PD-1与PD-L1的相互作用,是一类新型的免疫调节剂。
术语和简称
THF:四氢呋喃
DMF:N,N-二甲基甲酰胺
NBS:N-溴代邻苯二甲酰亚胺
BPO:过氧化苯甲酰
实施例1 2-羟基-4-(2-溴-3-苯基苄氧基)-5-氯苯甲醛
2-溴-3-苯基甲苯:
置2-溴-3-碘甲苯(350mg)于50ml单口瓶中,加入二氧六环/水(体积比5/1)搅拌,鼓吹氩气10min排除溶液中溶解的氧气,然后加入苯硼酸(172.65mg)碳酸铯(961.2mg),三苯基膦合钯(40.91mg)。氩气保护,80-100℃下搅拌12h。停止反应,降至室温,用硅藻土过滤。滤液减压浓缩后,加入水和乙酸乙酯萃取3
次。合并有机相,有机相用饱和食盐水洗涤,无水硫酸钠干燥,过滤,减压蒸干,得到2-溴-3-苯基甲苯无色油状物234mg。产率88%。1H NMR(400MHz,DMSO-d6),δ7.49–7.29(m,7H,Ar-H),7.14(d,1H,Ar-H),2.42(s,3H,Ar-CH3)。MS(FAB):248(M+1)。
2-溴-3-苯基苄溴;
称取原料2-溴-3-苯基甲苯(234mg)于100ml单口瓶中,加入20ml CCl4,使之溶解完全,搅拌下加入NBS(178mg),升温至80℃,回流,然后加入过氧化苯甲酰(4mg),2h后再次加入过氧化苯甲酰(4mg),继续反应2h,停止反应,冷至室温,加水淬灭反应,然后加入二氯甲烷和水进行萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,过滤,减压蒸干,得到2-溴-3-苯基苄溴黄色油状物262mg。直接用于下一步的反应。
2-羟基-4-(2-溴-3-苯基苄氧基)-5-氯苯甲醛:
称取2,4-二羟基-5-氯苯甲醛(73.94mg)置于50ml单口瓶中,以6ml无水乙腈溶解,然后加入碳酸氢钠(98.88mg)。室温搅拌40min后,将2-溴-3-苯基苄溴(192mg)溶于8ml DMF中,用恒压滴液漏斗缓慢加入至反应体系,加热回流至反应完全。降至室温,加入水和乙酸乙酯进行萃取。有机相用饱和食盐水洗涤,无水硫酸钠干燥,过滤,减压蒸干得到2-羟基-4-(2-溴-3-苯基苄氧基)-5-氯苯甲醛白色固体192mg。产率85%。1H NMR(400MHz,DMSO-d6)δ10.99(s,1H,-OH),10.03(s,1H,-CHO),7.64(d,1H,Ar-H),7.57(d,1H,Ar-H),7.45(m,4H,Ar-H),7.37(d,2H,Ar-H),6.67(d,1H,Ar-H),6.59(s,1H,Ar-H),5.25(s,2H,-CH2-)。MS(FAB):418(M+1)。
实施例2 N-乙酰胺乙基-2-(3-氰基苄氧基)-4-(2-溴-3-苯基苄氧基)-5-氯苄胺
2-(3-氰基苄氧基)-4-(2-溴-3-苯基苄氧基)-5-氯苯甲醛:
将2-羟基-4-(2-溴-3-苯基苄氧基)-5-氯苯甲醛(100mg)置于50ml单口瓶中,用6ml DMF溶解,加入碳酸铯(127.53mg)。室温搅拌15min后,滴加间氰基苄
溴(76.65mg)的DMF(4ml)溶液。在80℃下搅拌2h后停止反应。降至室温,加入水和乙酸乙酯萃取分液,有机相用饱和食盐水洗涤,无水硫酸钠干燥,过滤,减压蒸干,通过硅胶柱层析得到白色固体103mg。1H NMR(400MHz,DMSO-d6)δ10.26(s,1H,-CHO),8.00(s,1H,Ar-H),7.83(dd,2H,Ar-H),7.72(d,1H,Ar-H),7.61(t,2H,Ar-H),7.55–7.23(m,7H,Ar-H),6.95(s,1H,Ar-H),6.81(d,1H,Ar-H),5.35(s,2H,-CH2-),5.30(s,2H,-CH2-)。MS(FAB):509(M+1)。
N-乙酰胺乙基-2-(3-氰基苄氧基)-4-(2-溴-3-苯基苄氧基)-5-氯苄胺:
将2-(3-氰基苄氧基)-4-(2-溴-3-苯基苄氧基)-5-氯苯甲醛(50.8mg)溶于5ml DMF中,加入2-乙酰氨基乙胺(31.25mg),冰醋酸(36.75mg)至反应体系中。室温搅拌20min后,加入氰基硼氢化钠(19.23mg),25℃下搅拌14h。停止反应,加入水和乙酸乙酯萃取分离。有机相用饱和食盐水洗涤,无水硫酸钠干燥,过滤,减压蒸干,通过硅胶柱层析得到白色固体55mg。1H NMR(500MHz,DMSO-d6)δ8.00(s,1H,-ArH),7.86(dd,2H,-ArH),7.69–7.62(m,2H,-ArH),7.53(d,2H,-ArH),7.50(d,2H,-ArH),7.46(d,1H,-ArH),7.41(t,3H,-ArH),7.07(s,1H,-ArH),5.33(s,2H,-CH2-),5.32(s,2H,-CH2-),3.89(s,2H,-CH2-),3.25(m,2H,-CH2-),2.74(t,2H,-CH2-),1.83(s,3H,-COCH3).MS(FAB):620(M+1)。
实施例3 2-羟基-4-(2-溴-3-(3,4-乙二氧基苯基)苄氧基)-5-氯苯甲醛
2-溴-3-(3,4-乙二氧基苯基)甲苯:
用2-(3,4-乙二氧苯基)-4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷代替苯硼酸,用[1,1'-双(二苯基膦基)二茂铁]二氯化钯代替三苯基膦钯,碳酸钾代替碳酸铯,操作同实施例1,得到化合物2-溴-3-(3,4-乙二氧基苯基)甲苯,淡黄色油状物。1H NMR(400MHz,Chloroform-d)δ7.21(d,2H,-ArH),7.11(m,1H,-ArH),6.90(d,2H,-ArH),6.86(d,1H,-ArH),4.30(m,4H,-OCH2CH2O-),2.48(s,3H,-CH3).
2-羟基-4-(2-溴-3-(3,4-乙二氧基苯基)苄氧基)-5-氯苯甲醛:
用2-溴-3-(3,4-乙二氧基苯基)甲苯代替2-溴-3-甲基-1,1'-联苯,操作同实施例1进行溴化反应。得到的产物不经过分离直接与2,4-二羟基-5-氯苯甲醛进行下一步反应,操作同实施例1,得到白色固体。1H NMR(400MHz,DMSO-d6)δ10.91(s,1H,-OH),9.95(s,1H,-CHO),7.57(d,1H,-ArH),7.45(d,1H,-ArH),7.37(t,1H,-ArH),7.25(d,1H,-ArH),6.84(d,1H,-ArH),6.78(s,1H,-ArH),6.74(d,1H,-ArH),6.59(d,1H,-ArH),6.51(s,1H,-ArH),5.16(s,2H,-CH2-),4.20(m,4H,-OCH2CH2O-).MS(FAB):476(M+1)。
实施例4 N-(羟乙基)-2-(3-氰基苄氧基)-4-(2-溴-3-(3,4-二甲氧基苯基)苄氧基)-5-氯苄胺
2-(3-氰基苄氧基)-4-(2-溴-3-(3,4-乙二氧基苯基)苄氧基)-5-氯苯甲醛:
用2-羟基-4-(2-溴-3-(3,4-乙二氧基苯基)苄氧基)-5-氯苯甲醛代替2-羟基-4-(2-溴-3-苯基苄氧基)苯甲醛,操作同实施例2得到白色固体。1H NMR(400MHz,DMSO-d6)δ10.28(s,1H,-CHO),8.01(s,1H,-ArH),7.85(dd,2H,-ArH),7.74(d,1H,-ArH),7.63(t,1H,-ArH),7.58(d,1H,-ArH),7.46(t,1H,-ArH),7.35(d,1H,-ArH),6.94(d,2H,-ArH),6.87(s,1H,-ArH),6.82(d,2H,-ArH),5.36(s,2H,-CH2-),5.30(s,2H,-CH2-),4.29(m,4H,-OCH2CH2O-).MS(FAB):567(M+1)。
N-(羟乙基)-2-(3-氰基苄氧基)-4-(2-溴-3-(3,4-二甲氧基苯基)苄氧基)-5-氯苄胺:
用2-(3-氰基苄氧基)-4-(2-溴-3-(3,4-乙二氧基苯基)苄氧基)苯甲醛代替2-(3-氰基苄氧基)-4-(2-溴-3-苯基苄氧基)-5-氯苯甲醛,操作同实施例2,得到类白色固体粉末。1H NMR(400MHz,DMSO-d6)δ8.74(s,1H,-NH-),8.14(m,1H,-CONH-),8.00(s,
1H,-ArH),7.85(dd,2H,-ArH),7.63(t,1H,-ArH),7.54(d,1H,-ArH),7.50–7.37(m,2H,-ArH),7.33(d,1H,-ArH),6.94(d,1H,-ArH),6.86(s,2H,-ArH),6.82(d,1H,-ArH),6.74(d,1H,-ArH),5.27(s,2H,-CH2-),5.20(s,2H,-CH2-),4.29(m,4H,-OCH2CH2O-),4.13(s,2H,-CH2-),3.34-3.39(m,2H,-CH2-),2.96(m,2H,-CH2-),1.82(s,3H,-COCH3).MS(FAB):678(M+1)。
实施例5 2-羟基-4-(2-甲基-3-(3,4-乙二氧基苯基)苄氧基)-5-氯苯甲醛
以2-甲基-3-碘甲苯代替2-溴-3-碘甲苯为原料,操作同实施例1,得到白色固体2-羟基-4-(2-甲基-3-(3,4-乙二氧基苯基)苄氧基)-5-氯苯甲醛。MS(FAB):411(M+1),最后一步产率78%。
实施例6 (R)-N-[2-(5-氰基吡啶-3-亚甲氧基)-4-(2-甲基-3-(3,4-乙二氧基苯基)苄氧基)-5-氯苄基]-3-(吡啶-3-基)丙氨酸
用5-氰基吡啶-3-亚甲基溴代替间氰基苄溴,天冬酰胺代替2-乙酰氨基乙胺,操作同实施例2得到白色固体(R)-N-[2-(5-氰基吡啶-3-亚甲氧基)-4-(2-甲基-3-(3,4-乙二氧基苯基)苄氧基)-5-氯苄基]-3-(吡啶-3-基)丙氨酸。MS(FAB):678(M+1),产率48%。
实施例7 2-羟基-4-(2-氰基-3-(3,4-乙二氧基苯基)苄氧基)-5-溴苯甲醛
以2-氰基-3-碘甲苯代替2-溴-3-碘甲苯为原料,2,4-二羟基-5-溴苯甲醛代替2,4-二羟基-5-氯苯甲醛,操作同实施例1,得到白色固体2-羟基-4-(2-氰基-3-(3,4-乙二氧基苯基)苄氧基)-5-溴苯甲醛。MS(FAB):467(M+1),最后一步产率76%。
实施例8 N-(2-乙酰胺基乙基)-2-(3-氰基苄氧基)-4-(2-氰基-3-(3,4-二甲氧基苯基)苄氧基)苄胺
以2-羟基-4-(2-氰基-3-(3,4-乙二氧基苯基)苄氧基)-5-溴苯甲醛为原料,操作同实施例2得到白色固体N-(2-乙酰胺基乙基)-2-(3-氰基苄氧基)-4-(2-氰基-3-(3,4-二甲氧基苯基)苄氧基)苄胺。MS(FAB):668(M+1),产率46%。
注:实施例1、3、5、7是中间体2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I)
实施例2、4、6、8分别是在实施例1、3、5、7的基础上制备得到的有免疫调节作用的化合物
实施例5、6、7、8化合物是已知化合物
药理活性
体外活性评价:体外酶学水平的检测方法采用Cisbio公司的HTRF检测试剂盒。PD-1/PD-L1小分子抑制剂的筛选原理和方法
1、原理:PD-1蛋白带HIS标签,PD-1的配体PD-L1带hFc标签,分别用Eu标记的anti-hFc抗体和XL665标记的anti-HIS抗体与两个标签蛋白结合,激光激发后,能量能够从供体Eu上转移到受体XL665,使得XL665发光,而加入抑制剂(化合物或抗体)后,阻断PD-1与PD-L1的结合,使得Eu和XL665距离较远,能量不能转移,XL665不会发光。
2、实验方法:384孔白色酶标板,每孔加入2μl稀释液或者用稀释液稀释的目标化合物,然后每孔再加入4μl PD-1蛋白和4μl PD-L1蛋白,常温孵育15min,再每孔加入10μl anti-Tag1-Eu3+和anti-Tag2-XL665,室温孵育1h后检测665nm和620nm处的荧光信号。HTRF率=(665nm/620nm)*104。每个化合物检测8-10个浓度,采用Graphpad软件计算IC50。
3、筛选结果:
实施例 | IC50(M) | 实施例 | IC50(M) |
2 | 6.23×10-8 | 4 | 2.68×10-7 |
6 | 3.5×10-8 | 8 | 7.12×10-9 |
Claims (14)
- 根据权利要求2的制备方法,其特征在于,步骤1)中2-取代-3-碘甲苯衍生物1和芳基硼酸5或芳基硼酸酯发生Suzuki-Miyaura偶联反应生成2-取代-3-芳基甲苯衍生物2,是在钯催化和碱作用下进行。
- 根据权利要求3的制备方法,其特征在于,所述的钯催化剂可选自零价钯、二价钯化合物。
- 根据权利要求4的制备方法,其特征在于,所述的零价钯催化剂选自三苯膦合钯、四(三苯膦)钯,二价钯催化剂选自PdCl2(dppf)。
- 根据权利要求3的制备方法,其特征在于,所述的碱选自碱金属碳酸盐、碱金属醋酸盐。
- 根据权利要求6的制备方法,其特征在于,所述的碱金属碳酸盐选自碳酸铯、碳酸钾、碳酸钠,碱金属醋酸盐选自醋酸钠、醋酸钾。
- 根据权利要求2的制备方法,其特征在于,步骤2)中2-取代-3-芳基甲苯衍生物2与卤化剂在自由基引发条件下反应制备卤苄衍生物3。
- 根据权利要求8的制备方法,其特征在于,所述的卤化剂选自N-溴代丁二酰亚胺、N-氯代丁二酰亚胺、苯基三甲基三溴化铵、单质溴。
- 根据权利要求8的制备方法,其特征在于,所述的自由基引发条件是加入自由基引发剂或光照,或兼而有之。
- 根据权利要求10的制备方法,其特征在于,所述的自由基引发剂选自过氧化苯甲酰、或间氯过氧苯甲酸。
- 根据权利要求2的制备方法,其特征在于,步骤3)中,卤苄衍生物3和2,4-二羟基-5-取代苯甲醛6在弱碱性条件下选择性制备2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物(I)。
- 根据权利要求12的制备方法,其特征在于,所述的弱碱条件是加入碱金属碳酸氢盐,碱金属醋酸盐。
- 根据权利要求13的制备方法,其特征在于,所述的碱金属碳酸氢盐选自碳酸氢钠,或碳酸氢钾。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/303,650 US10815208B2 (en) | 2016-05-23 | 2017-05-23 | Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative |
CN201780031942.8A CN109153626B (zh) | 2016-05-23 | 2017-05-23 | 2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法 |
EP17802123.4A EP3459925B1 (en) | 2016-05-23 | 2017-05-23 | Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610343960.7 | 2016-05-23 | ||
CN201610343960 | 2016-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017202277A1 true WO2017202277A1 (zh) | 2017-11-30 |
Family
ID=60411053
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/085421 WO2017202277A1 (zh) | 2016-05-23 | 2017-05-23 | 2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法 |
PCT/CN2017/085420 WO2017202276A1 (zh) | 2016-05-23 | 2017-05-23 | 苯醚类衍生物、及其制法和药物组合物与用途 |
PCT/CN2017/085417 WO2017202273A1 (zh) | 2016-05-23 | 2017-05-23 | 苄苯醚类衍生物、及其制法和药物组合物与用途 |
PCT/CN2017/085418 WO2017202274A1 (zh) | 2016-05-23 | 2017-05-23 | 烟醇醚类衍生物、及其制法和药物组合物与用途 |
PCT/CN2017/085419 WO2017202275A1 (zh) | 2016-05-23 | 2017-05-23 | 溴代苄醚衍生物、及其制法和药物组合物与用途 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/085420 WO2017202276A1 (zh) | 2016-05-23 | 2017-05-23 | 苯醚类衍生物、及其制法和药物组合物与用途 |
PCT/CN2017/085417 WO2017202273A1 (zh) | 2016-05-23 | 2017-05-23 | 苄苯醚类衍生物、及其制法和药物组合物与用途 |
PCT/CN2017/085418 WO2017202274A1 (zh) | 2016-05-23 | 2017-05-23 | 烟醇醚类衍生物、及其制法和药物组合物与用途 |
PCT/CN2017/085419 WO2017202275A1 (zh) | 2016-05-23 | 2017-05-23 | 溴代苄醚衍生物、及其制法和药物组合物与用途 |
Country Status (7)
Country | Link |
---|---|
US (4) | US10975049B2 (zh) |
EP (4) | EP3466944B1 (zh) |
JP (3) | JP6905053B2 (zh) |
KR (3) | KR102456572B1 (zh) |
CN (10) | CN114853634A (zh) |
RU (3) | RU2735541C2 (zh) |
WO (5) | WO2017202277A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111978287A (zh) * | 2019-05-23 | 2020-11-24 | 中国科学院上海有机化学研究所 | 一类免疫检查点小分子抑制剂及其制备方法和用途 |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10975049B2 (en) | 2016-05-23 | 2021-04-13 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | Nicotinyl alcohol ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof |
CA3029256A1 (en) | 2016-06-27 | 2018-01-04 | Chemocentryx, Inc. | Immunomodulator compounds |
WO2018121560A1 (zh) * | 2016-12-29 | 2018-07-05 | 深圳微芯生物科技有限责任公司 | 脲类化合物、其制备方法及其应用 |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
IL272258B (en) | 2017-07-28 | 2022-08-01 | Chemocentryx Inc | Immunomodulator compounds |
MA49859A (fr) | 2017-08-08 | 2021-04-07 | Chemocentryx Inc | Immunomodulateurs macrocycliques |
SG11202007646UA (en) | 2018-02-13 | 2020-09-29 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
MA51232A (fr) | 2018-02-22 | 2020-10-07 | Chemocentryx Inc | Indane-amines utiles en tant qu'antagonistes de pd-l1 |
CA3093851A1 (en) * | 2018-03-29 | 2019-10-03 | Arbutus Biopharma Corporation | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same |
TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
EP3804758A4 (en) | 2018-05-31 | 2022-03-02 | ONO Pharmaceutical Co., Ltd. | BIOMARKER FOR ASSESSING THE EFFECTIVENESS OF AN IMMUNE CHECKPOINT INHIBITOR |
EP3810109A4 (en) | 2018-05-31 | 2022-03-16 | Peloton Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING CD73 |
TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
CN109305934A (zh) * | 2018-08-07 | 2019-02-05 | 成都海博锐药业有限公司 | 苯醚类衍生物及可药用盐、医药上的用途 |
CN110872275A (zh) * | 2018-08-31 | 2020-03-10 | 深圳微芯生物科技股份有限公司 | 作为免疫调节剂的联苯化合物及其用途 |
TW202028212A (zh) | 2018-10-11 | 2020-08-01 | 日商小野藥品工業股份有限公司 | Sting促效化合物 |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
US20220227733A1 (en) * | 2019-02-21 | 2022-07-21 | Adlai Nortye Biopharma Co., Ltd. | Pd-l1 antagonist compound |
CN109761952A (zh) * | 2019-02-25 | 2019-05-17 | 南方医科大学 | 一种含取代联苯的间苯二酚甲醚衍生物及其用途 |
CN111662270A (zh) * | 2019-03-05 | 2020-09-15 | 中国医学科学院药物研究所 | 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途 |
CN111714628B (zh) | 2019-03-22 | 2024-03-22 | 上海再极医药科技有限公司 | 小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用 |
BR112021022659A2 (pt) | 2019-05-15 | 2022-03-29 | Chemocentryx Inc | Compostos triarílicos para o tratamento de doenças pd-l1 |
CN112028870B (zh) * | 2019-06-04 | 2021-11-05 | 中国科学院上海药物研究所 | 一种具有苄氧基芳环结构的化合物,其制备方法和用途 |
EP3986392A4 (en) | 2019-06-20 | 2023-07-12 | ChemoCentryx, Inc. | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES |
JP2022539830A (ja) | 2019-07-10 | 2022-09-13 | ケモセントリックス,インコーポレイティド | Pd-l1阻害剤としてのインダン |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
US20220283167A1 (en) | 2019-08-05 | 2022-09-08 | Ono Pharmaceutical Co., Ltd. | Biomarkers for determining the efficacy of immune checkpoint inhibitors |
CN110256290A (zh) * | 2019-08-06 | 2019-09-20 | 宜春学院 | 一种4-氰基苄氧基-4′-氰基苯基醚的制备方法 |
CN111925318B (zh) * | 2019-09-09 | 2023-02-28 | 天津红日药业股份有限公司 | 一个烟醇醚衍生物的马来酸盐及其晶型和应用 |
BR112022006018A2 (pt) | 2019-10-16 | 2022-07-12 | Chemocentryx Inc | Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1 |
JP2022551972A (ja) | 2019-10-16 | 2022-12-14 | ケモセントリックス,インコーポレイティド | Pd-l1疾患の治療のためのヘテロアリール-ビフェニルアミン |
CN111187172B (zh) * | 2020-01-20 | 2021-10-29 | 中国药科大学 | 硝基苯醚类化合物、其制备方法和药物组合物与用途 |
AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
CN113444075B (zh) * | 2020-03-27 | 2024-06-21 | 中国医学科学院药物研究所 | 二氢吲哚衍生物、及其制法和药物组合物与用途 |
CN111333629B (zh) * | 2020-04-10 | 2021-03-05 | 颜建发 | 苯基-1h-吡唑类衍生物及其在抗肿瘤药物中的应用 |
JPWO2021205631A1 (zh) | 2020-04-10 | 2021-10-14 | ||
EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | CANCER THERAPY METHODS |
CN113563260A (zh) * | 2020-04-28 | 2021-10-29 | 药康众拓(江苏)医药科技有限公司 | 苯甲酰胺类化合物、制备方法及用途 |
BR112022022335A2 (pt) | 2020-05-05 | 2023-01-10 | Teon Therapeutics Inc | Moduladores de receptor canabinoide tipo 2 (cb2) e usos dos mesmos |
CN114075123B (zh) * | 2020-08-11 | 2023-06-06 | 中国人民解放军军事科学院军事医学研究院 | 苄胺类衍生物及其制备方法与用途 |
CN111943876B (zh) * | 2020-09-08 | 2022-04-19 | 江苏省原子医学研究所 | 一种n2s2类溴代苄醚衍生物、制备方法及应用 |
CN113135895A (zh) * | 2021-04-30 | 2021-07-20 | 中国药科大学 | 一种新型联苯类衍生物及其制备方法与医药用途 |
TW202325306A (zh) | 2021-09-02 | 2023-07-01 | 美商天恩治療有限公司 | 改良免疫細胞之生長及功能的方法 |
WO2023050104A1 (zh) * | 2021-09-28 | 2023-04-06 | 中国医学科学院药物研究所 | 二氢吲哚衍生物、及其制法和药物组合物与用途 |
WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
CN114181144B (zh) * | 2021-12-06 | 2023-04-04 | 浙江工业大学 | 一种氟代联苯甲基间苯二酚醚类衍生物、其制备方法和应用 |
WO2023104744A1 (en) * | 2021-12-06 | 2023-06-15 | Helmholtz-Zentrum Dresden-Rossendorf E.V. | 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof |
CN114956977B (zh) * | 2022-06-09 | 2024-03-26 | 朗捷睿(苏州)生物科技有限公司 | 一种联苯类化合物、药物组合物及其制备方法和应用 |
WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
CN115417870B (zh) * | 2022-09-20 | 2024-02-27 | 中国药科大学 | Pd-l1&nampt双靶点抑制剂和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4329518A (en) * | 1979-09-18 | 1982-05-11 | Fmc Corporation | Insecticidal [1,1'-biphenyl]-3-ylmethyl esters |
WO2015160641A2 (en) * | 2014-04-14 | 2015-10-22 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA816442B (en) * | 1980-10-02 | 1982-12-29 | Fmc Corp | Insecticidal(1,1'-biphenyl)-3-ylmethyl esters |
CN1128777C (zh) | 1994-08-04 | 2003-11-26 | 住友化学工业株式会社 | 二卤丙烯化合物,含有其的杀虫剂/杀螨剂和生产它们的中间体 |
US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
CN1735408A (zh) | 2002-11-08 | 2006-02-15 | 武田药品工业株式会社 | 受体机能调节剂 |
JP4594611B2 (ja) | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
JP2007114968A (ja) * | 2005-10-19 | 2007-05-10 | Junji Mizuma | バッテリの充電システムおよび充電方法 |
EP2001844A2 (en) | 2006-03-14 | 2008-12-17 | Amgen, Inc | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
RU2490266C2 (ru) * | 2008-12-05 | 2013-08-20 | Астеллас Фарма Инк. | Соединение 2н-хромена и его производное |
CN101735408B (zh) * | 2010-01-18 | 2011-12-21 | 中国海洋石油总公司 | 一种高装饰性醇酸-有机硅丙烯酸复合水性树脂 |
US8754066B2 (en) * | 2012-02-21 | 2014-06-17 | Allergan, Inc. | Phenoxy derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
CA2917614A1 (en) * | 2013-07-18 | 2015-01-22 | Novartis Ag | Aminomethyl-biaryl derivatives complement factor d inhibitors and uses thereof |
AU2014315457B2 (en) * | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
CN103787902B (zh) * | 2014-02-17 | 2016-08-17 | 华东理工大学 | 苄基取代的苯胺类化合物及其应用 |
US10975049B2 (en) | 2016-05-23 | 2021-04-13 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | Nicotinyl alcohol ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof |
-
2017
- 2017-05-23 US US16/303,649 patent/US10975049B2/en active Active
- 2017-05-23 JP JP2019514166A patent/JP6905053B2/ja active Active
- 2017-05-23 CN CN202210287082.7A patent/CN114853634A/zh active Pending
- 2017-05-23 KR KR1020187037129A patent/KR102456572B1/ko active IP Right Grant
- 2017-05-23 RU RU2018145296A patent/RU2735541C2/ru active
- 2017-05-23 CN CN201780031954.0A patent/CN109153670B/zh active Active
- 2017-05-23 US US16/303,650 patent/US10815208B2/en active Active
- 2017-05-23 EP EP17802120.0A patent/EP3466944B1/en active Active
- 2017-05-23 KR KR1020187037375A patent/KR102400592B1/ko active IP Right Grant
- 2017-05-23 CN CN201710365671.1A patent/CN107417572A/zh active Pending
- 2017-05-23 JP JP2019514168A patent/JP7075928B2/ja active Active
- 2017-05-23 CN CN201780031898.0A patent/CN109219592B/zh active Active
- 2017-05-23 EP EP17802119.2A patent/EP3450423B1/en active Active
- 2017-05-23 JP JP2019514167A patent/JP6980767B2/ja active Active
- 2017-05-23 CN CN201780031942.8A patent/CN109153626B/zh active Active
- 2017-05-23 CN CN201780031899.5A patent/CN109311792B/zh active Active
- 2017-05-23 CN CN201780031943.2A patent/CN109195960B/zh active Active
- 2017-05-23 EP EP17802123.4A patent/EP3459925B1/en active Active
- 2017-05-23 WO PCT/CN2017/085421 patent/WO2017202277A1/zh unknown
- 2017-05-23 WO PCT/CN2017/085420 patent/WO2017202276A1/zh unknown
- 2017-05-23 CN CN201710359979.5A patent/CN107417564A/zh active Pending
- 2017-05-23 US US16/303,646 patent/US10941129B2/en active Active
- 2017-05-23 CN CN201710363523.6A patent/CN107417506A/zh active Pending
- 2017-05-23 KR KR1020187037378A patent/KR102364344B1/ko active IP Right Grant
- 2017-05-23 US US16/303,641 patent/US10882833B2/en active Active
- 2017-05-23 WO PCT/CN2017/085417 patent/WO2017202273A1/zh unknown
- 2017-05-23 CN CN201710365696.1A patent/CN107417666A/zh active Pending
- 2017-05-23 WO PCT/CN2017/085418 patent/WO2017202274A1/zh unknown
- 2017-05-23 WO PCT/CN2017/085419 patent/WO2017202275A1/zh active Application Filing
- 2017-05-23 RU RU2018145534A patent/RU2744975C2/ru active
- 2017-05-23 EP EP17802122.6A patent/EP3459926B1/en active Active
- 2017-05-23 RU RU2018145009A patent/RU2743165C2/ru active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4329518A (en) * | 1979-09-18 | 1982-05-11 | Fmc Corporation | Insecticidal [1,1'-biphenyl]-3-ylmethyl esters |
WO2015160641A2 (en) * | 2014-04-14 | 2015-10-22 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
Non-Patent Citations (3)
Title |
---|
KUSUMA, B.R. ET AL.: "Synthesis and Evaluation of Novologues as C-Terminal Hsp90 Inhibitors with Cytoprotective Activity against Sensory Neuron Glucotoxicity", J. MED. CHEM., vol. 55, no. 12, 15 June 2012 (2012-06-15), pages 5797 - 5812, XP055195980 * |
See also references of EP3459925A4 * |
SMITH, R.C. ET AL.: "Suzuki and Heck Coupling Reactions Mediated by Palladium Complexes Bearing Trans-Spanning Diphosphines", JOURNAL OF ORGANOMETALLIC CHEMISTRY, vol. 690, no. 2, January 2005 (2005-01-01), pages 477 - 481, XP055554437 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111978287A (zh) * | 2019-05-23 | 2020-11-24 | 中国科学院上海有机化学研究所 | 一类免疫检查点小分子抑制剂及其制备方法和用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017202277A1 (zh) | 2-羟基-4-(2,3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法 | |
US9266872B2 (en) | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient | |
JP2016511237A (ja) | 選択的hdac3阻害剤 | |
MXPA06002391A (es) | Derivados de fluoreno. | |
JP6974869B2 (ja) | 乳癌の予防又は治療用の化合物 | |
AU2020271268A1 (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
WO2022107745A1 (ja) | Covid-19の治療剤又は予防剤 | |
US20100292279A1 (en) | Bis-(Sulfonylamino) Derivatives in Therapy | |
CN107879975B (zh) | 组蛋白去乙酰化酶抑制剂及其应用 | |
WO2009049492A1 (fr) | Composés de diaryléthers multi-substitués et d'aniline d'hydrocarbures aromatiques n-substitués | |
CN115304603A (zh) | 喹唑啉类抑制剂的制备及其应用 | |
CN107200716B (zh) | 苯并噁嗪类化合物及其制备方法与应用 | |
WO2023088095A1 (zh) | 一种7-氟-5-取代色胺类化合物及其制备方法和用途 | |
CN108947904B (zh) | 一种含有七元内酰胺环的化合物及其应用 | |
JP2019520359A (ja) | ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用 | |
CN115490689A (zh) | 不可逆krasg12c抑制剂的制备及其应用 | |
US20210107871A1 (en) | Biaryl sulfonamide derivative having filovirus cell entry inhibition activity | |
JP2022516922A (ja) | フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用 | |
KR102576102B1 (ko) | Uch37 탐지용 프로브 및 이의 용도 | |
CN115650904B (zh) | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 | |
EP4089077A1 (en) | Novel quinoline derivatives and uses thereof | |
KR101589632B1 (ko) | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 | |
WO2023001999A1 (en) | C2-thioether tryptophan trimers and tetramers for the treatment of betacoronoavirus infections | |
Hu et al. | An efficient synthesis of Erismodegib | |
Sagong | Design and synthesis of novel pan-targeting anti-influenza agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17802123 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017802123 Country of ref document: EP Effective date: 20181219 |